JNJ trades 5.2% above Wall Street's consensus target of $253.42.
Last 12 months price action with 12-month analyst target path
The base valuation assumes JNJ achieves its forward estimates and maintains a stable P/E multiple of 23.1x. This scenario reflects the blended consensus of 40 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of July 8, 2026, Johnson & Johnson (JNJ) has a Wall Street consensus price target of $253.42, based on estimates from 40 covering analysts. With the stock currently trading at $267.24, this represents a potential downside of -5.2%. The company has a market capitalization of $643.31B.
Analyst price targets range from a low of $208.00 to a high of $283.00, representing a 30% spread in expectations. The median target of $260.00 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 21 analysts rating the stock as a Buy or Strong Buy,16 rating it Hold, and 3 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, JNJ trades at a trailing P/E of 24.2x and forward P/E of 23.1x. The forward PEG ratio of 1.55 indicates reasonable valuation for growth. Analysts expect EPS to grow +34.5% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $277.14, with bear and bull scenarios of $174.60 and $365.16 respectively. Model confidence stands at 59/100, reflecting moderate uncertainty in projections.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
ABTAbbott Laboratories | $166.9B | $95.84 | $125.62 | +31.1% | Buy | 17.5x | 41 |
PFEPfizer Inc. | $136.9B | $24.07 | $26.75 | +11.1% | Hold | 8.1x | 39 |
MRKMerck & Co., Inc. | $318.3B | $128.86 | $133.77 | +3.8% | Buy | 25.1x | 37 |
LLYEli Lilly and Company | $1.2T | $1235.56 | $1269.94 | +2.8% | Buy | 33.7x | 45 |
BMYBristol-Myers Squibb Company | $118.4B | $57.97 | $62.60 | +8.0% | Hold | 9.2x | 41 |
ABBVAbbVie Inc. | $449.9B | $254.65 | $258.00 | +1.3% | Buy | 17.9x | 41 |
NVSNovartis AG | $299.6B | $157.03 | $170.00 | +8.3% | Hold | 18.0x | 25 |
SYKStryker Corporation | $120.1B | $313.38 | $387.46 | +23.6% | Buy | 20.9x | 51 |
MDTMedtronic plc | $107.6B | $83.83 | $95.80 | +14.3% | Buy | 14.1x | 51 |
BSXBoston Scientific Corporation | $67.3B | $45.30 | $82.40 | +81.9% | Buy | 13.5x | 44 |
Quick answers to the most common questions about buying JNJ stock.
Wall Street's consensus price target for JNJ is $253.42, -5.2% from its current price of $267.24. The below-market target from 40 analysts suggests limited near-term appreciation.
JNJ has a consensus rating of "Buy" based on 40 Wall Street analysts. The rating breakdown is predominantly bullish, with 21 Buy/Strong Buy ratings. The consensus 12-month price target of $253.42 implies -5.2% downside from current levels.
JNJ trades at a forward P/E of 23.0857x, representing a moderate valuation. With analysts targeting $253.42 (-5.2% implied move), the stock appears close to fair value.
The most bullish Wall Street analyst has a price target of $283 for JNJ, while the most conservative target is $208. The consensus of $253.42 represents the median expectation. Our quantitative valuation model projects a bull case target of $365 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
JNJ is heavily covered by Wall Street, with 40 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 21 have Buy ratings, 16 recommend Hold, and 3 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month JNJ stock forecast based on 40 Wall Street analysts shows a consensus price target of $253.42, with estimates ranging from $208 (bear case) to $283 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $277, with bear/bull scenarios of $175/$365.
Our quantitative valuation model calculates JNJ's fair value at $277 (base case), with a bear case of $175 and bull case of $365. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 59/100.
JNJ trades at a forward P/E ratio of 23.1x based on next-twelve-months earnings estimates compared to a trailing P/E of 24.2x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Analysts are cautious on JNJ, with 3 Sell ratings and a price target of $253.42 (-5.2% from current price). The "Buy" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
JNJ analyst price targets range from $208 to $283, a 30% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $253.42 consensus represents the middle ground. Our model's $175-$365 range provides an independent fundamental perspective.
Wall Street verdict, signals, and target summaries.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.